What insurance policy changes affect HCPCS Q5107?

There are 10 tracked policy changes affecting HCPCS Q5107, including updates from Missouri Medicaid (MO HealthNet), BCBS Tennessee, Florida Blue. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS Q5107?

Payers that have issued tracked updates for HCPCS Q5107 include: Missouri Medicaid (MO HealthNet), BCBS Tennessee, Florida Blue, Arkansas Blue Cross Blue Shield, Aetna, Cigna, New Jersey Medicaid.

How do I get notified when HCPCS Q5107 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS Q5107. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS Q5107?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

Q5107 — Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg: Insurance Policy Changes

Q5107 Insurance Policy Changes

HCPCS Q5107 is officially defined as "Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg." HCPCS Q5107 is referenced in 10 tracked payer policy changes from Missouri Medicaid (MO HealthNet), BCBS Tennessee, and 5 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q5107 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Policy Criteria Change

Arkansas Blue Cross Blue Shield·Effective Apr 1, 2026

Effective April 1, 2026, Walmart insurance will require prior authorization for all Bevacizumab, Infliximab, and Rituximab products (brand and biosimilars) across oncologic and non-oncologic indications. The policy establishes preferred biosimilar products (Mvasi, Zirabev, Avsola, Inflectra, Truxima, Riabni) that must be requested first, with non-preferred products (including Avastin, Remicade, Rituxan) requiring documented adverse events and FDA MedWatch reporting for exceptions.

Q5107 Insurance Policy Changes

Changes to Preferred Biosimilar Medications Effective October 1, 2026

Commercial BlueCare PAD_Step Therapy Guide

New Drug Waste Reduction Guideline

Policy Criteria Change

OfficeLink Updates - October 2025 notices and reminders (PDF)

Medicare Part B Step Therapy Product Updates

Updated Categories for Medicare Advantage Part B Step Therapy

Oncology drug dose rounding program: July 7 drug list update

Newsletter Vol. 32, No.07

Policy Criteria Change